Viruses for the treatment of cellular proliferative disorders
AssigneeOncolytics Biotech Inc.
InventorsMatthew C. Coffey, Bradley G. Thompson
Life of this patent
Estimating the term…
Abstract
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.
Claims54
A method for treating a neoplasm having at least one mutation in the ras gene in a mammal, comprising:
- (a) selecting a mammal with a neoplasm having at least one mutation in the ras gene wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to cells of the neoplasm an effective amount of a modified HSV under conditions which result in substantial lysis of the cells, wherein the modified HSV comprises a mutation in the γ134.5 gene.
A method of treating a neoplasm having at least one mutation in the ras gene in a human, comprising:
- (a) selecting a mammal with a neoplasm having at least one mutation in the ras gene wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to the neoplasm an effective amount of a modified HSV to result in substantial oncolysis of the neoplasm, wherein the modified HSV comprises a mutation in the γ134.5 gene.
A method of inhibiting metastasis of a neoplasm having at least one mutation in the ras gene in a mammal, comprising:
- (a) selecting a mammal with a neoplasm having at least one mutation in the ras gene wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to the neoplasm a modified HSV in an amount sufficient to result in substantial lysis of the neoplasm, wherein the modified HSV comprises a mutation in the γ134.5 gene.
Dependencies are inferred from the claim text.